We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

CDC to Roll out Cell Phone-Based Surveillance System for Monitoring COVID-19 Vaccine Recipients

By HospiMedica International staff writers
Posted on 26 Oct 2020
Illustration
Illustration
The US Centers for Disease Control and Prevention (CDC Atlanta, GA, USA) has added a new safety monitoring system to evaluate the safety of COVID-19 vaccines in real time and ensure that they are as safe as possible after they are authorized or approved for use.

Currently, clinical trials are evaluating investigational COVID-19 vaccines in many thousands of study participants to generate scientific data and other information for the Food and Drug Administration (FDA) to determine their safety and effectiveness. After a vaccine is authorized or approved for use, many vaccine safety monitoring systems watch for adverse events (possible side effects). This continued monitoring can pick up on adverse events that may not have been seen in clinical trials. If an unexpected adverse event is seen, experts quickly study it further to assess whether it is a true safety concern. Experts then decide whether changes are needed in vaccine recommendations. This monitoring is critical to help ensure that the benefits continue to outweigh the risks for people who receive vaccines.

As people get vaccinated, CDC, FDA, and other federal partners will use robust systems and data sources to conduct ongoing safety monitoring. Among its various safety monitoring systems, the CDC plans to use a new smartphone-based, after-vaccination health checker named V-SAFE for people who receive COVID-19 vaccines. V-SAFE is a smartphone-based text, text-to-web survey, and email-to-web survey active surveillance program for early vaccine recipients. V-SAFE uses contact information (phone numbers) from the registration process for COVID-19 vaccination of essential workers - up to 20+ million people during the first few months of a vaccination program.

V-SAFE will use text messaging and web surveys from CDC to check in with vaccine recipients for health problems following COVID-19 vaccination. V-SAFE will conduct health checks on vaccine recipients via text messages and email daily for the first week post-vaccination and weekly thereafter for six weeks post-vaccination. The system also will provide telephone follow up to anyone who reports medically significant (important) adverse events.

Related Links:
Centers for Disease Control and Prevention (CDC)

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Open Stapler
PROXIMATE Linear Cutter
New
High-Precision QA Tool
DEXA Phantom

Channels

Critical Care

view channel
Image: Researchers have taken a major step toward cuff-free blood pressure monitoring (Photo courtesy of Gwyneth Moe/Boston University)

Cuff-Free Blood Pressure Monitoring Device to Improve Early Detection and Management of Hypertension

Hypertension affects nearly half of all adults in the U.S. and remains the leading cause of cardiovascular disease. Regular and accurate blood pressure monitoring is essential for managing this condition,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more